Last updated: 10/29/2026 06:00:10

Evaluation of efficacy and safety of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in participants with relapsed/refractory multiple myelomaDREAMM 7

GSK study ID
207503
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Active, not recruiting
Active, not recruiting
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Trial description: This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Progression-free survival

Timeframe: Up to an average of 37 months

Secondary outcomes:

Complete response rate (CRR)

Timeframe: Up to 74 months

Overall response rate (ORR)

Timeframe: Up to 74 months

Clinical Benefit Rate (CBR)

Timeframe: Up to 74 months

Duration of response (DoR)

Timeframe: Up to 74 months

Time to response (TTR)

Timeframe: Up to 74 months

Time to Progression (TTP)

Timeframe: Up to 74 months

Overall survival (OS)

Timeframe: Up to 74 months

Progression-free survival on subsequent line of therapy (PFS2)

Timeframe: Up to 74 months

Minimal Residual Disease (MRD) negativity rate

Timeframe: Up to 74 months

Number of participants with adverse events (AEs)

Timeframe: Up to 74 months

Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters

Timeframe: Up to 74 months

Number of participants with abnormal ocular findings on ophthalmic examination

Timeframe: Up to 74 months

Plasma concentrations of belantamab mafodotin at indicated time points

Timeframe: Up to 74 months

Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points

Timeframe: Up to 74 months

Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin

Timeframe: Up to 74 months

Titers of ADAs against belantamab mafodotin

Timeframe: Up to 74 months

Number of Participants with Maximum post-baseline change from baseline in individual items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)

Timeframe: Up to 74 months

Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30)

Timeframe: Baseline and Up to 74 months

Change from Baseline in HRQoL as measured by EORTC IL52, 20-Item Multiple Myeloma Module (QLQ-MY20)

Timeframe: Baseline and Up to 74 months

Interventions:
Drug: Belantamab mafodotin
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone
Enrollment:
494
Primary completion date:
2023-02-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Multiple Myeloma
Product
belantamab mafodotin
Collaborators
Not applicable
Study date(s)
May 2020 to October 2029
Type
Interventional
Phase
3

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Pusan, Unmapped, 49241
Status
Unmapped
Location
GSK Investigational Site
Ulsan, Unmapped, 44033
Status
Study Complete
Location
GSK Investigational Site
Gent, Oost-Vlaanderen, Belgium, 9000
Status
Study Complete
Location
GSK Investigational Site
Krakow, Poland, 30510
Status
Unmapped
Location
GSK Investigational Site
Barcelona, Spain, 08916
Status
Unmapped
Location
GSK Investigational Site
Barcelona, Spain, 08035
Status
Unmapped
Location
GSK Investigational Site
Salamanca, Spain, 37007
Status
Study Complete
Location
GSK Investigational Site
Lublin, Poland, 20-081
Status
Unmapped
Location
GSK Investigational Site
Yuma, AZ, United States, 85364
Status
Unmapped
Location
GSK Investigational Site
Caceres, Spain, 10003
Status
Unmapped
Location
GSK Investigational Site
Lodz, Poland, 93-513
Status
Unmapped
Location
GSK Investigational Site
L'Hospitalet de Llobrega, Spain, 08908
Status
Unmapped
Location
GSK Investigational Site
Benowa, QLD, Australia, 4217
Status
Unmapped
Location
GSK Investigational Site
Tyler, TX, United States, 75702
Status
Study Complete
Location
GSK Investigational Site
Jette, Bruxelles, Belgium, 1090
Status
Unmapped
Location
GSK Investigational Site
Denver, NC, United States, 80128
Status
Unmapped
Location
GSK Investigational Site
Roeselare, Belgium, 8800
Status
Study Complete
Location
GSK Investigational Site
N Novgorod, Russia, 603126
Status
Unmapped
Location
GSK Investigational Site
Blue Ash, OH, United States, 45242-5665
Status
Unmapped
Location
GSK Investigational Site
Meldola FC, Italy, 47014
Status
Study Complete
Location
GSK Investigational Site
St Petersburg, Russia, 191024
Status
Unmapped
Location
GSK Investigational Site
Warszawa, Poland, 02-781
Status
Unmapped
Location
GSK Investigational Site
Woluwé-Saint-Lambert, Bruxelles, Belgium, 1200
Status
Unmapped
Location
GSK Investigational Site
Murcia, Spain, 30008
Status
Study Complete
Location
GSK Investigational Site
Tel Aviv, Israel, 64239
Status
Study Complete
Location
GSK Investigational Site
Saratov, Russia, 410028
Status
Unmapped
Location
GSK Investigational Site
Poznan, Poland, 60-569
Status
Unmapped
Location
GSK Investigational Site
DORDRECHT, Zuid-Holland, Netherlands, 3318 AT
Status
Unmapped
Location
GSK Investigational Site
GRONINGEN, Netherlands, 9713 GZ
Status
Unmapped
Location
GSK Investigational Site
Nowy Sacz, Poland, 33-300
Status
Unmapped
Location
GSK Investigational Site
Novosibirsk, Russia, 630087
Status
Unmapped
Location
GSK Investigational Site
Athens, Greece, 11528
Status
Unmapped
Location
GSK Investigational Site
Alexandroupoli, East Macedonia And Thrace, Greece, 681 00
Status
Study Complete
Location
GSK Investigational Site
Jinan, China, 250012
Status
Study Complete
Location
GSK Investigational Site
Saint-Petersburg, Russia, 197 089
Status
Unmapped
Location
GSK Investigational Site
Mission, KS, United States, 66205-2005
Status
Unmapped
Location
GSK Investigational Site
Shenyang, China, 110001
Status
Study Complete
Location
GSK Investigational Site
Gifu, Japan, 503-8502
Status
Study Complete
Location
GSK Investigational Site
Nagano, Japan, 392-8510
Status
Unmapped
Location
GSK Investigational Site
Ehime, Japan, 790-8524
Status
Unmapped
Location
GSK Investigational Site
Aichi, Japan, 467-8602
Status
Unmapped
Location
GSK Investigational Site
Okayama, Japan, 701-1192
Status
Study Complete
Location
GSK Investigational Site
Osaka, Japan, 530-0012
Status
Study Complete
Location
GSK Investigational Site
Hyogo, Japan, 670-8540
Status
Unmapped
Location
GSK Investigational Site
Beijing, China, 100191
Status
Study Complete
Location
GSK Investigational Site
Fukuoka, Japan, 810-8563
Status
Unmapped
Location
GSK Investigational Site
Osaka, Japan, 545-8586
Status
Unmapped
Location
GSK Investigational Site
Fukuoka, Japan, 806-8501
Status
Study Complete
Location
GSK Investigational Site
Fukuoka, Japan, 807-8555
Status
Study Complete
Location
GSK Investigational Site
Kanagawa, Japan, 221-0855
Status
Study Complete
Location
GSK Investigational Site
Fukuoka, Japan, 815-8555
Status
Study Complete
Location
GSK Investigational Site
Kochi, Japan, 781-8555
Status
Study Complete
Location
GSK Investigational Site
Aichi, Japan, 441-8570
Status
Unmapped
Location
GSK Investigational Site
Aomori, Japan, 030-8553
Status
Unmapped
Location
GSK Investigational Site
Bergamo, Italy, 24127
Status
Study Complete
Location
GSK Investigational Site
Chorzow, Poland, 41-500
Status
Unmapped
Location
GSK Investigational Site
Gijon, Spain, 33394
Status
Study Complete
Location
GSK Investigational Site
Gunma, Japan, 377-0280
Status
Unmapped
Location
GSK Investigational Site
Kanagawa, Japan, 247-8533
Status
Unmapped
Location
GSK Investigational Site
Liverpool, NSW, Australia, 2170
Status
Unmapped
Location
GSK Investigational Site
Lublin, Poland, 20-090
Status
Unmapped
Location
GSK Investigational Site
Milano, Italy, 20133
Status
Study Complete
Location
GSK Investigational Site
Moscow, Russia, 125284
Status
Unmapped
Location
GSK Investigational Site
PamplonaNavarra, Spain, 31008
Status
Study Complete
Location
GSK Investigational Site
Shizuoka, Japan, 411-8777
Status
Study Complete
Location
GSK Investigational Site
Siena, Italy, 53100
Status
Study Complete
Location
GSK Investigational Site
Thessaloniki, Greece, 54007
Status
Unmapped
Location
GSK Investigational Site
Ufa, Russia, 450083
Status
Study Complete
Location
GSK Investigational Site
Wollongong, NSW, Australia, 2500
Status
Study Complete
Location
GSK Investigational Site
Aichi, Japan, 446-8602
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chiba, Japan, 296-8602
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fukushima, Japan, 960-1295
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hokkaido, Japan, 060-8648
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kyoto, Japan, 602-8566
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Seongnam-si Gyeonggi-do, Unmapped, 13620
Status
Study Complete
Location
GSK Investigational Site
Seoul, Unmapped, 06351
Status
Unmapped
Location
GSK Investigational Site
Seoul, Unmapped, 06591
Status
Unmapped
Location
GSK Investigational Site
Edmonton, AB, Canada, T6G 1Z2
Status
Unmapped
Location
GSK Investigational Site
London, ON, Canada, N6A 5W9
Status
Unmapped
Location
GSK Investigational Site
Leicester, United Kingdom, LE1 5WW
Status
Unmapped
Location
GSK Investigational Site
Samara, Russia, 443021
Status
Study Complete
Location
GSK Investigational Site
Stoke on Trent, United Kingdom, ST4 6QG
Status
Unmapped
Location
GSK Investigational Site
Dundee, United Kingdom, DD1 9SY
Status
Unmapped
Location
GSK Investigational Site
Würzburg, Bayern, Germany, 97080
Status
Unmapped
Location
GSK Investigational Site
Sutton, United Kingdom, SM2 5PT
Status
Unmapped
Location
GSK Investigational Site
Montreal, QC, Canada, H4J 1C5
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 28007
Status
Unmapped
Location
GSK Investigational Site
MOstoles Madrid, Spain, 28933
Status
Unmapped
Location
GSK Investigational Site
Pozuelo de AlarcOn Madr, Spain, 28223
Status
Unmapped
Location
GSK Investigational Site
Bournemouth, United Kingdom, BH7 7DW
Status
Unmapped
Location
GSK Investigational Site
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
Status
Unmapped
Location
GSK Investigational Site
Koeln, Germany, 50937
Status
Unmapped
Location
GSK Investigational Site
München, Bayern, Germany, 81377
Status
Unmapped
Location
GSK Investigational Site
Jena, Thüringen, Germany, 07747
Status
Study Complete
Location
GSK Investigational Site
Ulm, Baden-Württemberg, Germany, 89081
Status
Unmapped
Location
GSK Investigational Site
London, United Kingdom, W12 0NN
Status
Unmapped
Location
GSK Investigational Site
Bologna, Italy, 40138
Status
Unmapped
Location
GSK Investigational Site
SAo Paulo, Brazil, 04537-080
Status
Unmapped
Location
GSK Investigational Site
Florianopolis, Santa Catarina, Brazil, 88020-210
Status
Unmapped
Location
GSK Investigational Site
Amiens cedex 1, France, 80054
Status
Study Complete
Location
GSK Investigational Site
Nice cedex 3, France, 06200
Status
Study Complete
Location
GSK Investigational Site
Rennes, France, 35033
Status
Study Complete
Location
GSK Investigational Site
Caen cedex 9, France, 14033
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
Status
Unmapped
Location
GSK Investigational Site
Newcastle, NSW, Australia, 2298
Status
Unmapped
Location
GSK Investigational Site
SAo Paulo, Brazil, 05403-000
Status
Unmapped
Location
GSK Investigational Site
Joinville, Brazil, 89201-260
Status
Unmapped
Location
GSK Investigational Site
Rio de Janeiro, Brazil, 22775001
Status
Unmapped
Location
GSK Investigational Site
Tianjin, China, 300020
Status
Unmapped
Location
GSK Investigational Site
Natal, Brazil, 59075-740
Status
Unmapped
Location
GSK Investigational Site
Roanoke, VA, United States, 24014
Status
Study Complete
Location
GSK Investigational Site
Brescia, Italy, 25123
Status
Unmapped
Location
GSK Investigational Site
Roma, Italy, 00168
Status
Unmapped
Location
GSK Investigational Site
Wellington, New Zealand, 6021
Status
Study Complete
Location
GSK Investigational Site
Dunedin, New Zealand, 9054
Status
Study Complete
Location
GSK Investigational Site
Christchurch, New Zealand, 8011
Status
Unmapped
Location
GSK Investigational Site
Takapuna Auckland, New Zealand, 1309
Status
Study Complete
Location
GSK Investigational Site
Torino, Italy, 10126
Status
Study Complete
Location
GSK Investigational Site
Catania, Italy, 95123
Status
Unmapped
Location
GSK Investigational Site
Nedlands, WA, Australia, 6009
Status
Unmapped
Location
GSK Investigational Site
Camperdown, NSW, Australia, 2050
Status
Unmapped
Location
GSK Investigational Site
Melbourne, VIC, Australia, 3004
Status
Unmapped
Location
GSK Investigational Site
Murdoch, WA, Australia, 6150
Status
Unmapped
Location
GSK Investigational Site
Box Hill, VIC, Australia, 3128
Status
Unmapped
Location
GSK Investigational Site
Heidelberg, VIC, Australia, 3084
Status
Unmapped
Location
GSK Investigational Site
Ashford, SA, Australia, 5037
Status
Unmapped
Location
GSK Investigational Site
Herston, QLD, Australia, 4029
Status
Unmapped
Location
GSK Investigational Site
Paris, France, 75651
Status
Unmapped
Location
GSK Investigational Site
St Leonards, NSW, Australia, 2065
Status
Unmapped
Location
GSK Investigational Site
Ostrava, Unmapped, 708 52
Status
Unmapped
Location
GSK Investigational Site
Jerusalem, Israel, 91120
Status
Unmapped
Location
GSK Investigational Site
Ramat Gan, Israel, 52621
Status
Study Complete
Location
GSK Investigational Site
Kfar Saba, Israel, 44281
Status
Study Complete
Location
GSK Investigational Site
Hradec Kralove, Unmapped, 500 05
Status
Unmapped
Location
GSK Investigational Site
Praha 2, Unmapped, 128 08
Status
Unmapped
Location
GSK Investigational Site
Brno, Unmapped, 625 00
Status
Unmapped
Location
GSK Investigational Site
Zhengzhou, China, 450052
Status
Unmapped
Location
GSK Investigational Site
Changchun, China, 130012
Status
Unmapped
Location
GSK Investigational Site
Suzhou, China, 215006
Status
Unmapped
Location
GSK Investigational Site
Guangzhou, China, 510060
Status
Unmapped
Location
GSK Investigational Site
Toronto, ON, Canada, M4N 3M5
Status
Study Complete
Location
GSK Investigational Site
GUANGZHOU, China, 510515
Status
Unmapped
Location
GSK Investigational Site
Hangzhou, China, 310003
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 31008
Status
Study Complete
Location
GSK Investigational Site
Nanjing, China, 210008
Status
Unmapped
Location
GSK Investigational Site
Beijing, China, 100020
Status
Unmapped
Location
GSK Investigational Site
Cardiff, United Kingdom, CF14 4XW
Status
Unmapped
Location
GSK Investigational Site
Ravenna, Italy, 48121
Status
Unmapped

Study documents

Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Active, not recruiting
Actual primary completion date
2023-02-10
Actual study completion date
Not applicable

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website